Actelion creates Vaxxilon together with the Max Planck society

ALLSCHWIL, SWITZERLAND - 26 June 2015 - Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic carbohydrate vaccines.

The new company, Vaxxilon, aims to discover, develop, and commercialize synthetic carbohydrate vaccines. Vaxxilon has licensed exclusive rights to multiple preclinical vaccine candidates and additional technologies from Max-Planck Innovation GmbH, the technology transfer office of the Max Planck Society.

Actelion is the principal investor and majority shareholder, having made a funding commitment of up to €30 million, to be released in tranches over a period of three to four years.

Jean-Paul Clozel, MD and Chief Executive Officer of Actelion, commented: "Actelion has had success in advancing the science of the endothelium, and translating it into therapeutic options for the PAH community. Our long-term success depends on building additional specialty areas. We have been impressed by the work performed by the team of Prof. Seeberger and I am very happy that Actelion can help to translate this work into prophylactic and therapeutic options."

The first preclinical candidates were discovered and synthesized by Prof. Dr. Peter Seeberger and his team at the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany, near Berlin. An additional key component of the technology was jointly developed by Prof. Seeberger and Prof. Gennaro de Libero of the University Hospital of Basel. Vaxxilon plans to advance its first vaccine candidate into man within 3 years.

Jean-Paul Clozel concluded: "Synthetic carbohydrate vaccines represent an exciting opportunity and have great potential. By creating Vaxxilon with the Max Planck Society we are building a platform from which synthetic carbohydrate vaccines could become a commercial reality within the next decade. This investment represents an innovative way to find synergies between the academic and industrial worlds."

Prof. Dr. Seeberger, Director at the Max Planck Institute for Colloids and Interfaces, commented: "I am very proud that the ground-breaking research and technology from the Max Planck Society in cooperation with my colleague at the University Hospital of Basel, Prof. Gennaro de Libero, will be advanced in the form of Vaxxilon. I believe that the speed and flexibility of a small company, combined with Actelion's financial backing, will allow this novel vaccine technology to progress and eventually be made available to society quickly and efficiently. This new class of vaccines promises to be perhaps more efficient, faster and more reproducible to create and manufacture, and has advantages of distribution and administration which may improve access to vaccines around the world."

Vaxxilon will be led by Tom Monroe who has served in multiple and varied roles of growing responsibility at Actelion over the past 15 years. Four accomplished chemists from Prof. Seeberger's group will form the initial scientific team at Vaxxilon, and recruitment will begin quickly for additional experienced personnel. Vaxxilon, a Swiss limited liability company, will be headquartered in Reinach, Switzerland, and a research facility will be established in Berlin.

The company will be overseen by a Board of Directors with representatives of Actelion, Prof. Seeberger, and an independent director as well as an observer from the Max Planck Society. David Stout, recently elected to the Actelion Board of Directors, and former President of Pharmaceutical Operations at GlaxoSmithKline, will serve as chairman.

ABOUT VAXXILON

Vaxxilon AG is dedicated to the discovery, development and commercialization of innovative synthetic carbohydrate vaccines to prevent, first and foremost, bacterial infections. Vaxxilon has licensed multiple preclinical vaccine candidates to target pathogens for which there are no approved vaccines, or for which existing vaccines do not fully meet medical needs. Vaxxilon was created in 2015 by Actelion Ltd and the Max Planck Society. The company is based on the scientific insights and innovation of Professors Peter Seeberger of the Max Planck Institute of Colloids and Interfaces and Gennaro de Libero of the University Hospital of Basel. For more information see www.vaxxilon.com